Epizyme retrieves global rights to cancer drug in $110M deal

Pumped by the potential commercial impact of their EZH2 inhibitor EPZ-6438, Epizyme ($EPZM) is dragging back global rights to the drug in what the Cambridge, MA-based biotech is calling a "transformative" deal. Epizyme is paying Eisai $40 million upfront, with another $70 million on the table in clinical and regulatory milestones to unwind their earlier partnership. In short order the biotech then plans to begin a Phase II in non-Hodgkin lymphoma, with another study in the works for INI1-deficient solid tumors, such as synovial sarcoma and malignant rhabdoid tumor. "As we began to see the quality and duration of the responses, including two complete responses, in relapsed and refractory NHL and INI1-deficient patients treated with EPZ-6438 as a monotherapy, it became clear to us that having worldwide development and commercialization responsibility for a targeted therapeutic like 6438 would be transformative for Epizyme," CEO Robert Gould said in a statement. Eisai is keeping rights for the drug in Japan. Epizyme shares were down 15% in mid-morning trading after the company reported a $15 million loss for the last quarter. Release

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.